Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients

Mezquita, Laura; Benito, Amparo; Ruano-Raviña, Alberto; Zamora, Javier; Olmedo, María Eugenia; Reguera, Pablo; Madariaga, Ainhoa; Villamayor, María; Cortez, Silvia Patricia; Gorospe, Luis; Santón, Almudena; Mayoralas, Sagrario; Hernánz, R.; Cabañero, Alberto; Auclin, Édouard; Carrato, Alfredo; Garrido, Pilar

doi:10.1016/j.cllc.2019.04.009

Cited by 9 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, available data concerning the specific histological features of radon-induced tumours are scarce. Mezquita et al first report that well and moderated differentiated histological grades were more frequent in patients exposed to radon higher concentrations (>148 Bq/m 3 ), papillary histological pattern being the most commonly found, particularly in cases exposed to >200 Bq/m 3 [38]. Nonetheless, there is still little information about the clinical characteristics of the subjects that will develop lung cancer associated with radon.…”

Section: General Populationmentioning

confidence: 99%

Radon and Lung Cancer: Current Trends and Future Perspectives

Riudavets

Herreros

Besse

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Lung cancer is a public health problem and the first cause of cancer death worldwide. Radon is a radioactive gas that tends to accumulate inside homes, and it is the second lung cancer risk factor after smoking, and the first one in non-smokers. In Europe, there are several radon-prone areas, and although the 2013/59 EURATOM directive is aimed to regulate indoor radon exposition, regulating measures can vary between countries. Radon emits alpha-ionizing radiation that has been linked to a wide variety of cytotoxic and genotoxic effects; however, the link between lung cancer and radon from the genomic point of view remains poorly described. Driver molecular alterations have been recently identified in non-small lung cancer (NSCLC), such as somatic mutations (EGFR, BRAF, HER2, MET) or chromosomal rearrangements (ALK, ROS1, RET, NTRK), mainly in the non-smoking population, where no risk factor has been identified yet. An association between radon exposure and oncogenic NSCLC in non-smokers has been hypothesised. This paper provides a practical, concise and updated review on the implications of indoor radon in lung cancer carcinogenesis, and especially of its potential relation with NSCLC with driver genomic alterations.

show abstract

Section: General Populationmentioning

confidence: 99%

Radon and Lung Cancer: Current Trends and Future Perspectives

Riudavets

Herreros

Besse

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…It was observed that the occurrence of EGFR, BRAF, HER2 and ROS1 was significantly higher in areas with high radon exposure, while KRAS mutations were more frequent in areas with low exposure [118]. More recent research of Mezquita et al tried to answer the question if there is any link between the genetic diversity of non-small-cell lung cancer and exposure to indoor radon, Although it was conducted in a small group of patients the research led to the conclusion that indoor radon concentrations exceeded those recommended by WHO, and despite the fact that there were no differences between groups with EGFR, ALK, and BRAF patients, the concentrations above the WHO recommendations were most common with ALK rearrangement and BRAF mutation [119].…”

Section: Radon and Lung Cancermentioning

confidence: 99%

Radon—The Element of Risk. The Impact of Radon Exposure on Human Health

Grzywa-Celińska

Krusiński

Mazur

et al. 2020

Toxics

View full text Add to dashboard Cite

Lung cancer is a heterogeneous group of diseases with multifactorial aetiology. Smoking has been undeniably recognized as the main aetiological factor in lung cancer, but it should be emphasized that it is not the only factor. It is worth noting that a number of nonsmokers also develop this disease. Radon exposure is the second greatest risk factor for lung cancer among smokers—after smoking—and the first one for nonsmokers. The knowledge about this element amongst specialist oncologists and pulmonologists seems to be very superficial. We discuss the impact of radon on human health, with particular emphasis on respiratory diseases, including lung cancer. A better understanding of the problem will increase the chance of reducing the impact of radon exposure on public health and may contribute to more effective prevention of a number of lung diseases.

show abstract

“…238,239,249 While ROS1-rearranged NSCLC is similar to ALK-rearranged NSCLC in that it is associated with a younger age at presentation (median: 49.8 years) and adenocarcinoma histology, significant associations do not hold for smoking, especially in Asian cohorts, and indoor radon gas exposure has been identified as a primary risk factor in nonsmokers. 238,[249][250][251] In terms of histology, ROS1 signet-ring cells are also prevalent in Western populations while in an evaluation of over 500 Chinese patients with advanced NSCLC, 11 of 16 (68.8%) ROS1 fusion-positive tumors had hepatoid cytology or cribriform structure. 249,250 Overall, prognosis with ROS1 is favorable with 40% alive at 4 years without targeted therapy and 60% alive with targeted therapy.…”

Section: Ros1 Fusionsmentioning

confidence: 99%

Targeted Therapy for Non-Small Cell Lung Cancer

Noor

Cummings

Johnson

et al. 2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Lung cancer is a heterogeneous disease, and the availability of comprehensive genomic profiling has allowed for the characterization of its molecular subtypes. This has increased the ability to deliver “personalized medicines” by tailoring therapies to target driver mutations in a patient's cancer. The development of targeted therapies for non-small cell lung cancer (NSCLC) has helped define the era of precision medicine throughout oncology. This article aims to contextualize recent research and provide an updated summary of targeted therapies available for patients with NSCLC. With practitioners and clinical researchers in mind, we note standard of care therapies, important approvals, practice guidelines, and treatments in development. The first section discusses mutations in the epidermal growth factor receptor (EGFR) gene, and the second section examines rearrangements in the anaplastic lymphoma kinase (ALK) and ROS1 fusions. Finally, we explore the rarer molecular alterations in BRAF, RET, MET, HER2, and KRAS. Given the many available therapies, it is important to understand the molecular alterations in NSCLC, and how to target them.

show abstract

Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients

Cited by 9 publications

References 18 publications

Radon and Lung Cancer: Current Trends and Future Perspectives

Radon and Lung Cancer: Current Trends and Future Perspectives

Radon—The Element of Risk. The Impact of Radon Exposure on Human Health

Targeted Therapy for Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About